What is Xenon Pharmaceuticals's change in other liabilities?

Xenon Pharmaceuticals (XENE) reported change in other liabilities of $47K in Q1 2026.

What does change in other liabilities mean?

Change in miscellaneous liabilities affecting operating cash flow.

Xenon Pharmaceuticals XENE Change in Other Liabilities

Change in Other Liabilities at other companies

Johnson & JohnsonJNJ

-$629M+90.3%

Jazz PharmaceuticalsJAZZ

$12.2M+321%

BridgeBio PharmaBBIO

$4.62M+56.8%

Roivant SciencesROIV

-$252K-230%

BiogenBIIB

-$62M-38.8%

Ionis PharmaceuticalsIONS

$21M+6,207%

Other financials

Income statement

See full

Revenue--100%

Operating income-$112.3M-54.4%

Net income-$102.3M-57.3%

EPS (diluted)-$1.17-41.0%

Balance sheet

See full

Cash & equivalents$545.9M+368%

Total debt$7.5M-13.6%

Total equity$1.3B+90.0%

Total assets$1.4B+86.6%

Cash flow

See full

Operating cash flow-$88.9M-44.2%

CapEx$133.0K+209%

Free cash flow-$89.0M-44.3%

Valuation

See full

Market cap$5.11B+116%

Profitability

See full

Operating margin-4,974.3%—

Net margin-4,612.1%—

FCF margin-3,732.2%—

Returns & leverage

See full

Return on equity-37.5%+8.7pp

Debt / equity0×0.0×

Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xenon Pharmaceuticals's change in other liabilities?: Xenon Pharmaceuticals (XENE) reported change in other liabilities of $47K in Q1 2026.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.